Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Last updated: July 31, 2025
Sponsor: Peking Union Medical College
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rosacea

Scalp Disorders

Hidradenitis Suppurativa

Treatment

Secukinumab

Clinical Study ID

NCT07109765
No. I-24PJ1844
  • Ages > 18
  • All Genders

Study Summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age ≥18 years

  • diagnosis of moderate-to-severe HS with Hurley stage II or III

  • Disease duration of ≥6 months, presence of at least one draining tunnel or twoinflammatory nodules

  • inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNFinhibitors

Exclusion

Exclusion Criteria:

  • active infections (e.g., viral hepatitis, active tuberculosis)

  • use of other biologics or systemic immunosuppressants within the past three months

  • severe organ dysfunction (e.g., hepatic or renal failure)

  • any other conditions that might affect study results

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Secukinumab
Phase:
Study Start date:
June 01, 2025
Estimated Completion Date:
June 01, 2026

Connect with a study center

  • No. 1 Shuai Fu Yuan, Dongcheng District, Beijing

    Beijing, Beijing 100730
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.